Patents Examined by Tori Strong
  • Patent number: 11103499
    Abstract: Compounds of Formula I: or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof, processes and intermediates for preparation thereof, compositions thereof, and uses thereof, are provided. Pharmaceutical compositions comprising a compound of formula I and a compound of Formula II: or enantiomers thereof, metabolites thereof, derivatives thereof, deuterated derivatives thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, N-oxides thereof, or a combination thereof. Compositions and methods for improving the efficacy of DEX, or providing beneficial pharmacokinetic effects to DEX, comprising co-administering a compound of formula I or SARPO, and a compound of Formula II or DEX to a subject in need thereof, and dosage forms, drug delivery systems, methods of treatment thereof.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: August 31, 2021
    Inventors: Sreenivasarao Vepachedu, Hans J Moebius, Anton Bespalov
  • Patent number: 11077086
    Abstract: The present invention relates to solid dosage forms of cannabinoid pharmaceutical formulations comprising a solvated cannabinoid for buccal or sublingual administration, and methods of making and using the same.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: August 3, 2021
    Assignee: Pharmaceutical Productions, Inc.
    Inventor: John A. McCarty
  • Patent number: 11072598
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: July 27, 2021
    Assignee: CRINETICS PHARMACEUTICALS, INC.
    Inventors: Sangdon Han, Sun Hee Kim, Yunfei Zhu
  • Patent number: 11066400
    Abstract: The present invention relates to a FoxM1 gene splicing modifier selected from a compound of formula (I) or of formula (VI) wherein A and B are as defined herein, or a pharmaceutically acceptable salt thereof, for use in the treatment, prevention and/or delay of progression of cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 20, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Friedrich Metzger, Hasane Ratni
  • Patent number: 11065225
    Abstract: Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce Aß expression; (ii) reduce Aß aggregation: (iii) maintain APP expression; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK3ß protein; (vi) decrease the expression of GSK3ß protein; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein expression, in said patient without severe psychological impairments and side effects associated with higher doses of THC.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: July 20, 2021
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventor: Chuanhai Cao
  • Patent number: 11058672
    Abstract: A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: July 13, 2021
    Assignee: CHIESI FARMACEUTICA S.P.A.
    Inventors: Rajeshwar Motheram, Gopal Krishna, Min Ding, Keith Flood, Kornepati Ramakrishna
  • Patent number: 11046702
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: June 29, 2021
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
  • Patent number: 11033545
    Abstract: The present disclosure relates to the use of negative allosteric modulators (NAMs) of the metabotropic glutamate receptor 5 (mGluR5) in the treatment of a mature brain damage, such as damage after stroke.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 15, 2021
    Assignee: Sinntaxis AB
    Inventors: Tadeusz Wieloch, Carin Sjölund, Kerstin Beirup, Karsten Ruscher, Roger Olsson
  • Patent number: 11021437
    Abstract: The present invention relates to a pharmaceutical composition for the treatment of anaphylaxis formulated for rapid delivery, in one embodiment, the delivery vehicle is a rapidly dissolving film. The films contain an epinephrine or a novel epinephrine pro-drag for fee rapid treatment of anaphylaxis in a patient. This invention relates to pharmaceutical compositions made by modifying the physicochemical properties of epinephrine in order to enhance its permeability through biological membranes (sublingual and buccal membranes). Several prodrugs of epinephrine are shown by modifying the two hydroxyl (phenolic) groups in positions 3 and 4 on the benzene ring, by chemically reacting the two groups with several acid moieties to form an ester bond with different alkyl chains. The addition of an alkyl group will enhance the lipophilicity of epinephrine (increase log P) and will consequently increase its permeability through the biological membranes (sublingual and buccal tissues in the oral cavity).
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: June 1, 2021
    Assignee: IONO Pharma, LLC
    Inventor: Hassan Almoazen
  • Patent number: 11020365
    Abstract: This invention relates to a mixture of at least three fatty acids selected from palmitic acid, oleic acid, stearic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), azelaic acid and myristic acid. This invention also relates to the use of the aforesaid mixture in the treatment of inflammatory pathologies.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: June 1, 2021
    Assignee: AGAIN LIFE ITALIA SRL
    Inventor: Lodovico Burattin
  • Patent number: 11013744
    Abstract: The present invention relates to the treatment of solid tumors in humans such as cancer, especially colorectal cancer (CRC), which involves administering the diastereomerically pure folate adjuvant [6R]-5,10-methylenetetrahydrofolate in 5-fluorouracil (5-FU) based chemotherapy.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: May 25, 2021
    Assignee: Isofol Medical AB
    Inventors: Per L. Lindberg, Anders Vedin, Gunnel E. Sundén, Bengt Gustavsson
  • Patent number: 10993939
    Abstract: The present disclosure is directed to compositions and methods for treating or preventing vasomotor symptoms such as hot flashes, comprising a Transient Receptor Potential Melastatin 8 (TRPM8) antagonist and administering a TRPM8 antagonist, respectively.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: May 4, 2021
    Assignee: Mitsubishi Tanabe Pharmaceutical Company
    Inventor: Joseph M. Palumbo
  • Patent number: 10980778
    Abstract: The invention features methods for inhibiting the formation, reducing the size, and slowing the growth of an osteochondroma in a subject with multiple osteochondroma (MO) by administering to the subject palovarotene (also known as R667), or a pharmaceutically acceptable salt thereof. The methods described herein can also ameliorate complications associated with osteochondroma formation and growth in a subject with MO.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: April 20, 2021
    Assignee: Clementia Pharmaceuticals Inc.
    Inventors: Isabelle Lemire, Michael Harvey, Donna Roy Grogan, Clarissa Desjardins
  • Patent number: 10980766
    Abstract: The invention provides use of entacapone, an entacapone derivative or a stereoisomer, hydride, or pharmaceutically-acceptable salt thereof, in a person in need thereof, to treat or inhibit macular degeneration or age-related macular degeneration, and related compostions.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: April 20, 2021
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Niu Huang, Shiming Peng
  • Patent number: 10980795
    Abstract: Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: April 20, 2021
    Inventors: Eliel Bayever, Navreet Dhindsa, Jonathan Basil Fitzgerald, Peter Laivins, Victor Moyo, Clet Niyikiza, Jaeyeon Kim
  • Patent number: 10980775
    Abstract: The present invention relates to a pharmaceutical composition or medical device comprising a fucoidan and at least one compound of formula A or B: wherein R1 and R2 are independently selected from the group consisting of —OH, —CH3, —CF3CH2O—, and CH3O—. Such pharmaceutical composition or medical device is notably useful for the treatment and/or prevention of a skin disorder involving excessive angiogenesis and/or fibrogenesis, such as in skin fibrosis, angiofibromas, hamartomas and periungual fibromas, skin manifestation occurring with rosacea, acne, atopic dermatitis, scleroderma, psoriasis and lupus erythematosus, and especially of Tuberous Sclerosis Complex and skin manifestation occurring with Tuberous Sclerosis Complex.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: April 20, 2021
    Assignee: Xantial
    Inventor: Gilles Henri Lasserre
  • Patent number: 10959964
    Abstract: The present invention relates to ambroxol hydrochloride for the treatment of acute pharyngitis, wherein ambroxol hydrochloride as a sprayable composition comprising up to 30 mg/ml ambroxol hydrochloride is administered locally in a dose of 1 to 20 mg.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: March 30, 2021
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Sandra Sauerland, Julia Elisabeth Boni, Bernd Karl Plohmann
  • Patent number: 10952973
    Abstract: Provided are a production method of a pregabalin-containing composition, which suppresses crystallization of pregabalin, and a pregabalin-containing composition that shows suppressed crystallization of Pregabalin. The production method of the pregabalin-containing composition of the present invention contains steps of: (1) dissolving pregabalin in an aqueous solution of an acid to prepare an aqueous solution of a salt of pregabalin; (2) mixing the aqueous solution of pregabalin salt and a hydrophilic resin to prepare a mixture thereof; and (3) concentrating the mixture; wherein the acid has an acid dissociation constant lower than that of pregabalin.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: March 23, 2021
    Assignee: NITTO DENKO CORPORATION
    Inventors: Tomohito Takita, Kaiji Fujiwara, Chie Matsumoto, Akinori Sugiyama, Jyun Isayama, Toshinari Honda, Ai Funasaki
  • Patent number: 10952962
    Abstract: Disclosed herein is a ready-to-use liquid formulation comprising lidocaine hydrochloride and epinephrine hydrochloride. Also disclosed herein is a process for preparing a ready-to-use liquid formulation comprising lidocaine hydrochloride and epinephrine hydrochloride, as well as methods for using the ready-to-use liquid formulation.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: March 23, 2021
    Assignee: QuVa Pharma, Inc.
    Inventors: Travis A. Leeah, Jianping Chen
  • Patent number: 10952963
    Abstract: Disclosed herein is a ready-to-use liquid formulation comprising ropivacaine, epinephrine, clonidine, and ketorolac (collectively referred to as RECK). Also disclosed herein is a process for preparing the RECK-containing liquid formulation, as well as methods for using the same.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: March 23, 2021
    Assignee: QuVa Pharma, Inc.
    Inventors: Travis A. Leeah, Jianping Chen